Stocks News

Annovis Bio: Search for efficacy against Alzheimer’s disease (NYSE:ANVS)

businessman

D-none

Monday, April 29th, Annovis Bio (New York Stock Exchange:ANVS) announced primary results from a phase 2/3 Alzheimer’s disease (AD) clinical trial. This test was described as follows:

The Phase 2/3 study was a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetop.

Related Articles

Back to top button